The Catalyst

Most Recent Posts

09.14.12 | By Preet Bilinski

This summer there have been two high-profile Alzheimer's drug failures. These setbacks are extremely disappointing to us all but particularly for patients and their families, health care providers, and the researchers working on these potential new medicines.

09.14.12

In case you missed it, there's a very interesting meta-analysis in this week's Annals of internal Medicine on the comparative effectiveness of interventions to improve medication adherence.

09.13.12 | By Preet Bilinski

Alzheimer's disease is the sixth leading cause of death in the United States today, with more than 5 million people currently affected.

09.13.12 | By John Castellani

At the Newseum last night, here in Washington, I was privileged to be part of an event honoring some truly inspiring and remarkable people.

09.12.12 | By Preet Bilinski

Below is a guest blog post from Chris deVries, the Chief Executive Officer/Executive Vice-President of the American Association for Geriatric Psychiatry (AAGP). AAGP is a national association representing and serving its members and the field of geriatric psychiatry and promotes the mental health and well-being of older people.

09.12.12 | By Mark Grayson

Great news for patients with HIV/ AIDS who cannot afford their medicine.

09.12.12 | By Jennifer Wall

In a blog post today, Pharmalot delves into various opinions on biopharmaceutical research and development (R&D) spending.

09.11.12 | By Jennifer Wall

Today we're featuring a blog post from Val Halamandaris, the President of the National Association for Home Care and Hospice (NAHC).

09.07.12 | By Mark Grayson

With the start of the next round of negotiations for the Trans Pacific Partnership in Leesburg, Virginia many Americans probably do not know how important these talks are to U.S. jobs and exports. The biopharmaceutical sector directly employed more than 650,000 U.S. workers in 2009, supporting a total of 4 million jobs [in areas such as construction, trucking, and information technology.

09.07.12 | By John Castellani

The clock is ticking as we count down the remaining days until the first ever Research and Hope Award ceremony, where we will have the privilege of honoring individuals who have made incredible sacrifices in the great battle against Alz

09.07.12

Ten thousand baby boomers will turn 65 today. This will happen again tomorrow, the next day and every day until 2030. With such a significant growth in Medicare eligible Americans, ensuring effective coverage and access to medicines well into the future is a priority.

09.06.12

Yet more proof of the value of exercise - at every age.

09.05.12 | By Jennifer Wall

As part of our "From Hope to Cures" guest blog series, below is a post from the Alzheimer's Foundation of America President and CEO, Eric J. Hall, on the significant research and progress that will help lead to innovative treatments.

09.05.12

My first anniversary as a PhRMA road warrior traveling from state to state to help educate legislators, health policymakers, reporters and others about industry clinical trials of new medicines is rapidly approaching.

08.30.12

A strong U.S. biopharma industry is vital to ensuring the health of our nation's economy and citizens. Investment in R&D supports jobs within a variety of U.S. industries. The below infographic explains how only with a strong and growing biopharma sector can we add jobs, reduce long term healthcare costs and prolong the quality of life for all Americans.

Pages